{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:04:02Z","timestamp":1793880242746,"version":"4.7.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.gene.2022.146930","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T02:40:51Z","timestamp":1664764851000},"page":"146930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Adaptive resistance is not responsible for long-term drug resistance in a cellular model of triple negative breast cancer"],"prefix":"10.1016","volume":"850","author":[{"given":"Uttom","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Castellanos-Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean T.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Yag\u00fce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gene.2022.146930_b0005","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10549-017-4202-z","article-title":"Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer","volume":"163","author":"Asaduzzaman","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.gene.2022.146930_b0010","doi-asserted-by":"crossref","unstructured":"Bai, S., Ingram, P., Chen, Y.C., Deng, N., Pearson, A., Niknafs, Y.S., et al., 2016. EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian Cancer Cells. Cancer Res., 76(21), 6396-409.","DOI":"10.1158\/0008-5472.CAN-16-0225"},{"issue":"10","key":"10.1016\/j.gene.2022.146930_b0015","first-page":"3741","article-title":"p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor","volume":"29","author":"Bocangel","year":"2009","journal-title":"Anticancer Res."},{"issue":"8","key":"10.1016\/j.gene.2022.146930_b0020","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1128\/MCB.01072-10","article-title":"SPATA18, a spermatogenesis-associated gene, is a novel transcriptional target of p53 and p63","volume":"31","author":"Bornstein","year":"2011","journal-title":"Mol. Cell Biol."},{"issue":"9","key":"10.1016\/j.gene.2022.146930_b0025","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of Multidrug Resistance in Cancer Chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.gene.2022.146930_b0030","doi-asserted-by":"crossref","unstructured":"Chau, B.N., Diaz, R.L., Saunders, M.A., Cheng, C., Chang, A.N., Warrener, P., et al., 2009. Identification of SULF2 as a novel transcriptional target of p53 by use of integrated genomic analyses. Cancer Res., 69(4), 1368-74.","DOI":"10.1158\/0008-5472.CAN-08-2742"},{"issue":"31","key":"10.1016\/j.gene.2022.146930_b0035","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1038\/onc.2014.332","article-title":"Topoisomerase IIalpha in chromosome instability and personalized cancer therapy","volume":"34","author":"Chen","year":"2015","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.lungcan.2005.04.013","article-title":"Aberrant methylation of FBN2 in human non-small cell lung cancer","volume":"50","author":"Chen","year":"2005","journal-title":"Lung Cancer."},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00239-019-09914-3","article-title":"Antimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence","volume":"88","author":"Christaki","year":"2020","journal-title":"J. Mol. Evol."},{"issue":"4","key":"10.1016\/j.gene.2022.146930_b0050","first-page":"1106","article-title":"Network rewiring, adaptive resistance and combating strategies in breast cancer","volume":"2","author":"Cremers","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.gene.2022.146930_b0055","doi-asserted-by":"crossref","unstructured":"Dan, X., Babbar, M., Moore, A., Wechter, N., Tian, J., Mohanty, J.G., et al., 2020. DNA damage invokes mitophagy through a pathway involving Spata18. Nucleic Acids Res.; 48(12), 6611-23.","DOI":"10.1093\/nar\/gkaa393"},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-84492-3","article-title":"Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer","volume":"11","author":"De Vita","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.gene.2022.146930_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.628690","article-title":"Activation of PI3K\/AKT\/mTOR Pathway Causes Drug Resistance in Breast Cancer","volume":"12","author":"Dong","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2011.01.001","article-title":"Creeping baselines and adaptive resistance to antibiotics","volume":"14","author":"Fernandez","year":"2011","journal-title":"Drug Resist. Updat."},{"issue":"20","key":"10.1016\/j.gene.2022.146930_b0075","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-Negative Breast Cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"New Engl. J. Med."},{"issue":"10","key":"10.1016\/j.gene.2022.146930_b0080","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.3390\/ijms21103543","article-title":"PHLD Class Proteins: A Family of New Players in the p53 Network","volume":"21","author":"Fuselier","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.gene.2022.146930_b0085","first-page":"474","article-title":"Lipid Metabolism and Resistance to Anticancer Treatment","volume":"9","author":"Germain","year":"2020","journal-title":"Biology (Basel)"},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/bjc.1990.219","article-title":"Establishment and characterisation of a new tumorigenic cell line with a normal karyotype derived from a human breast adenocarcinoma","volume":"62","author":"Gioanni","year":"1990","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.gene.2022.146930_b0095","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fonc.2013.00120","article-title":"Targeting nuclear factor-kappa B to overcome resistance to chemotherapy","volume":"3","author":"Godwin","year":"2013","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.gene.2022.146930_b0100","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jhep.2011.08.022","article-title":"p53, a novel regulator of lipid metabolism pathways","volume":"56","author":"Goldstein","year":"2012","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.gene.2022.146930_b0105","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1128\/MCB.16.4.1500","article-title":"The cell cycle-coupled expression of topoisomerase IIalpha during S phase is regulated by mRNA stability and is disrupted by heat shock or ionizing radiation","volume":"16","author":"Goswami","year":"1996","journal-title":"Mol. Cell Biol."},{"issue":"49","key":"10.1016\/j.gene.2022.146930_b0110","doi-asserted-by":"crossref","first-page":"38384","DOI":"10.1074\/jbc.M005298200","article-title":"Cell cycle-coupled variation in topoisomerase IIalpha mRNA is regulated by the 3'-untranslated region. Possible role of redox-sensitive protein binding in mRNA accumulation","volume":"275","author":"Goswami","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1593\/neo.121312","article-title":"WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer","volume":"15","author":"Griesmann","year":"2013","journal-title":"Neoplasia."},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0120","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-8-375","article-title":"Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells","volume":"8","author":"Guo","year":"2008","journal-title":"BMC Cancer."},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0125","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Disease Primers."},{"issue":"10","key":"10.1016\/j.gene.2022.146930_b0130","first-page":"4371","article-title":"FBN2 methylation is detected in the serum of colorectal cancer patients with hepatic metastasis","volume":"32","author":"Hibi","year":"2012","journal-title":"Anticancer Res."},{"issue":"10","key":"10.1016\/j.gene.2022.146930_b0135","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer."},{"issue":"3","key":"10.1016\/j.gene.2022.146930_b0140","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers."},{"key":"10.1016\/j.gene.2022.146930_b0145","doi-asserted-by":"crossref","unstructured":"Ibrahim Al-Obaide, M.A., Arutla, V., Bacolod, M.D., Wang, W., Zhang, R., Srivenugopal, K.S., 2021. Genomic Space of MGMT in Human Glioma Revisited: Novel Motifs, Regulatory RNAs, NRF1, 2, and CTCF Involvement in Gene Expression. Int. J. Mol. Sci., 22(5).","DOI":"10.3390\/ijms22052492"},{"issue":"5","key":"10.1016\/j.gene.2022.146930_b0150","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.cdd.4401843","article-title":"Signals from within: the DNA-damage-induced NF-kappaB response","volume":"13","author":"Janssens","year":"2006","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.gene.2022.146930_b0155","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3892\/or.2014.3468","article-title":"Microarray-based detection and expression analysis of extracellular matrix proteins in drugresistant ovarian cancer cell lines","volume":"32","author":"Januchowski","year":"2014","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0160","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41418-020-00606-w","article-title":"TRIM22 activates NF-kappaB signaling in glioblastoma by accelerating the degradation of IkappaBalpha","volume":"28","author":"Ji","year":"2021","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.gene.2022.146930_b0165","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000245937","article-title":"Doxorubicin exerts cytotoxic effects through cell cycle arrest and Fas-mediated cell death","volume":"84","author":"Kim","year":"2009","journal-title":"Pharmacology"},{"key":"10.1016\/j.gene.2022.146930_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114692","article-title":"MicroRNA-495\/TGF-beta\/FOXC1 axis regulates multidrug resistance in metaplastic breast cancer cells","volume":"192","author":"Kumar","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.gene.2022.146930_b0175","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41568-022-00454-5","article-title":"Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer","volume":"22","author":"Labrie","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"20","key":"10.1016\/j.gene.2022.146930_b0180","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s00018-008-8111-5","article-title":"An overview of cancer multidrug resistance: a still unsolved problem","volume":"65","author":"Lage","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"issue":"11","key":"10.1016\/j.gene.2022.146930_b0185","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3390\/genes10110859","article-title":"Cell Cycle-Dependent Control and Roles of DNA Topoisomerase II","volume":"10","author":"Lee","year":"2019","journal-title":"Genes (Basel)"},{"issue":"6","key":"10.1016\/j.gene.2022.146930_b0190","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database Hallmark Gene Set Collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"issue":"37","key":"10.1016\/j.gene.2022.146930_b0195","doi-asserted-by":"crossref","first-page":"62069","DOI":"10.18632\/oncotarget.18911","article-title":"TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT\/GSK3beta\/beta-catenin signaling in non-small cell lung cancer","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget."},{"issue":"4","key":"10.1016\/j.gene.2022.146930_b0200","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/1878-0261.13037","article-title":"Lineage-specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture","volume":"16","author":"Liverani","year":"2022","journal-title":"Mol. Oncol."},{"issue":"3","key":"10.1016\/j.gene.2022.146930_b0205","doi-asserted-by":"crossref","first-page":"108657","DOI":"10.1016\/j.celrep.2020.108657","article-title":"Deep neural networks identify signaling mechanisms of ErbB-family drug resistance from a continuous cell morphology space","volume":"34","author":"Longden","year":"2021","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0210","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-01624-4","article-title":"DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer","volume":"7","author":"Lund","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.gene.2022.146930_b0215","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-021-03456-7","article-title":"BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism","volume":"12","author":"Luo","year":"2021","journal-title":"Cell Death Dis."},{"issue":"4","key":"10.1016\/j.gene.2022.146930_b0220","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.gene.2022.146930_b0225","doi-asserted-by":"crossref","unstructured":"McFadyen, M.C.E., Melvin, W.T., Murray, G.I., 2004. Cytochrome P450 enzymes: Novel options for cancer therapeutics. Mol. Cancer Ther., 3(3), 363-71.","DOI":"10.1158\/1535-7163.363.3.3"},{"issue":"2","key":"10.1016\/j.gene.2022.146930_b0230","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev."},{"issue":"11","key":"10.1016\/j.gene.2022.146930_b0235","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1084\/jem.188.11.2033","article-title":"p53 activates the CD95 (APO-1\/Fas) gene in response to DNA damage by anticancer drugs","volume":"188","author":"M\u00fcller","year":"1998","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.gene.2022.146930_b0240","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00280-022-04400-y","article-title":"Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells","volume":"89","author":"Nicoletto","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.gene.2022.146930_b0245","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10585-018-9903-0","article-title":"The challenge of drug resistance in cancer treatment: a current overview","volume":"35","author":"Nikolaou","year":"2018","journal-title":"Clin. Exp. Metastasis."},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0250","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s43556-021-00041-4","article-title":"Drug resistance: from bacteria to cancer","volume":"2","author":"Patel","year":"2021","journal-title":"Mol. Biomed."},{"issue":"2","key":"10.1016\/j.gene.2022.146930_b0255","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bcp.2012.10.020","article-title":"Loss of O(6)-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells","volume":"85","author":"Raguz","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"S2","key":"10.1016\/j.gene.2022.146930_b0260","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2573","article-title":"Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone","volume":"12","author":"Rivera","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.gene.2022.146930_b0265","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.3389\/fonc.2020.01152","article-title":"Role of DNA Methylation in the Resistance to Therapy in Solid Tumors","volume":"10","author":"Romero-Garcia","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12108-6","article-title":"The CXCL5\/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis","volume":"10","author":"Romero-Moreno","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0275","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16199-4","article-title":"Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer","volume":"11","author":"Saatci","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.gene.2022.146930_b0280","article-title":"SGK1 in Human Cancer: Emerging Roles and Mechanisms","volume":"10","author":"Sang","year":"2020","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.gene.2022.146930_b0285","doi-asserted-by":"crossref","first-page":"101293","DOI":"10.1016\/j.isci.2020.101293","article-title":"Identifying States of Collateral Sensitivity during the Evolution of Therapeutic Resistance in Ewing's Sarcoma","volume":"23","author":"Scarborough","year":"2020","journal-title":"iScience"},{"issue":"2","key":"10.1016\/j.gene.2022.146930_b0290","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.canlet.2015.12.011","article-title":"Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells","volume":"372","author":"Sharma","year":"2016","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.gene.2022.146930_b0295","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.gene.2022.146930_b0300","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neo.2018.02.008","article-title":"Nephronectin is Correlated with Poor Prognosis in Breast Cancer and Promotes Metastasis via its Integrin-Binding Motifs","volume":"20","author":"Steigedal","year":"2018","journal-title":"Neoplasia."},{"issue":"3","key":"10.1016\/j.gene.2022.146930_b0305","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"7782","key":"10.1016\/j.gene.2022.146930_b0310","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.gene.2022.146930_b0315","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10549-012-2167-5","article-title":"TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy","volume":"135","author":"Wang","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0320","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1128\/MCB.17.1.389","article-title":"Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor","volume":"17","author":"Wang","year":"1997","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0325","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1097\/CAD.0000000000001153","article-title":"Knockdown of CXCL5 inhibits the invasion, metastasis and stemness of bladder cancer lung metastatic cells by downregulating CD44","volume":"33","author":"Wang","year":"2022","journal-title":"Anticancer Drugs."},{"key":"10.1016\/j.gene.2022.146930_b0330","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1476-4598-10-16","article-title":"Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin","volume":"10","author":"Wei","year":"2011","journal-title":"Mol. Cancer."},{"key":"10.1016\/j.gene.2022.146930_b0335","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2199-8-36","article-title":"Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions","volume":"8","author":"Williams","year":"2007","journal-title":"BMC Mol. Biol."},{"key":"10.1016\/j.gene.2022.146930_b0340","doi-asserted-by":"crossref","first-page":"174147","DOI":"10.1016\/j.ejphar.2021.174147","article-title":"The role of CD44 in cancer chemoresistance: A concise review","volume":"903","author":"Yaghobi","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.gene.2022.146930_b0345","doi-asserted-by":"crossref","unstructured":"Yague, E., Arance, A., Kubitza, L., O'Hare, M., Jat, P., Ogilvie, C.M., et al., 2007. Ability to acquire drug resistance arises early during the tumorigenesis process. Cancer Res., 67(3), 1130-7.","DOI":"10.1158\/0008-5472.CAN-06-2574"},{"issue":"14","key":"10.1016\/j.gene.2022.146930_b0350","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/sj.gt.3302269","article-title":"Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1","volume":"11","author":"Yague","year":"2004","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0355","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13046-020-01682-z","article-title":"Histone methyltransferase and drug resistance in cancers","volume":"39","author":"Yang","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.gene.2022.146930_b0360","doi-asserted-by":"crossref","first-page":"8976","DOI":"10.1038\/s41598-021-88258-9","article-title":"SCD5 expression correlates with prognosis and response to neoadjuvant chemotherapy in breast cancer","volume":"11","author":"Zhao","year":"2021","journal-title":"Sci. Rep."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111922007508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111922007508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T16:59:22Z","timestamp":1759856362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111922007508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":72,"alternative-id":["S0378111922007508"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2022.146930","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adaptive resistance is not responsible for long-term drug resistance in a cellular model of triple negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2022.146930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"146930"}}